公司資料
Aziyo Biologics 股價、新聞與催化劑
- 股票代碼:
- AZYO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
The latest monitored company update is “Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch.” The corresponding closing-price reaction is not yet available.
公司概覽
Drug-Eluting Biomatrix Company
Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site.
Antibiotic-Eluting Platform
The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first applied around implantable cardiac devices and is now being extended into plastic and reconstructive surgery.
NXT-41
NXT-41 is a biologic matrix intended for soft-tissue reinforcement in plastic and reconstructive procedures. It serves as the non-antibiotic foundation for the broader product family.
NXT-41x
NXT-41x adds local antibiotic elution to the biomatrix, with the goal of reducing infection risk in reconstructive surgery while preserving tissue integration.
未來催化劑
- FDA clearance decision for NXT-41 in the fourth quarter of 2026.
- FDA clearance decision for NXT-41x in the first half of 2027.
- Commercial soft launch of NXT-41x in the second half of 2027.
- Full commercial launch of NXT-41x in 2028.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。